Citations 0
September 17, 2003

Glycoprotein IIb/IIIa Inhibition in Percutaneous Coronary Interventions—Reply

Author Affiliations

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2003;290(11):1451. doi:10.1001/jama.290.11.1451-a

To the Editor: Dr Lincoff and colleagues1 reported that patients who received bivalirudin with provisional glycoprotein IIb/IIIa (Gp IIb/IIIa) blockade after percutaneous coronary intervention (PCI) had a risk of acute ischemic events similar to that of those who received heparin plus planned Gp IIb/IIIa blockade. They also reported that bivalirudin was associated with less bleeding. We have 2 concerns, however, about the generalizability of these results.

First Page Preview View Large
First page PDF preview
First page PDF preview